SCHEMBL29985609

SCHEMBL29985609

CCCC(C(=O)O)c1c(C)nc2sc(C)cc2c1-c1ccccc1

nearest known ligand 0.86

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PSIP1 O75475 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL99991 0.92 PSIP1 (0.61) PSIP1
SCHEMBL99925 0.82 PSIP1 (0.49) PSIP1
SCHEMBL10325642 0.78 PSIP1 (0.59) PSIP1
SCHEMBL29985176 0.78 PSIP1 (0.59) PSIP1
SCHEMBL99632 0.76
SCHEMBL99100 0.76 PSIP1 (0.59) PSIP1
SCHEMBL99279 0.75
SCHEMBL135618 0.74 PSIP1 (0.41) PSIP1
SCHEMBL99295 0.74 PSIP1 (0.54) PSIP1
SCHEMBL29450576 0.73 PSIP1 (0.45) PSIP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220323494-A1 Novel Control Switch GLAXOSMITHKLINE IP DEV LTD (GB) 2022-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220323494-A1 Novel Control Switch TNFRSF9, TNFRSF1A, TNFSF11 PSIP1 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.